Healthpluser

Spread the love

<figure class="img_container" style="float:left;margin-right:10px;width:350px;;margin-bottom:5px;max-width:100%;"><img width="590" height="442" class="unveil" loading="eager" style="width:100%;max-height:100%" src="https://img.etb2bimg.com/files/cp/upload-1716881542-ethealthworld.webp" data-src="https://etimg.etb2bimg.com/photo/118243476.cms" captionrendered="1" alt=""><figcaption class="caption"></figcaption></figure>Bengaluru: Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes. Dexcom’s shares fell nearly 37per cent last year, largely due to a slump in July after the company slashed its annual revenue forecast, blaming a restructuring of its sales team, fewer customers and lower revenue. <!– PROMOSLOT_M –> In July, the company said that based on the compounding effect of lower second-quarter new customer starts, it expects the growth rate in the back half of the year to be impacted. It reiterated its previous 2025 revenue estimate of $4.60 billion. Analysts on average were expecting revenue of $4.61 billion, as per data compiled by LSEG. <!– PROMOSLOT –> The company reported fourth-quarter revenue of $1.11 billion slightly above the analysts’ consensus estimate of $1.10 billion. <!– PROMOSLOT_M –> The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and older who do not use insulin, making it the first CGM available for over-the-counter sales. Increasing <a id="21411276" type="General" weightage="20" keywordseo="diabetes-care" source="keywords" class="news-keywords" href="/tag/diabetes+care">diabetes care</a> awareness, wider insurance coverage, and preference for devices that do not need finger pricks have benefited CGMs such as Dexcom’s Stelo and G7. Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom’s Stelo debut. <!– PROMOSLOT_M –> The company is counting on further international expansion to drive growth after it said it had improved access to its devices in markets such as Japan and France last quarter. <!– PROMOSLOT –> On an adjusted basis, the company earned a profit of 45 cents per share, compared to estimates of 50 cents per share. (Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona) </body>","next_sibling":[{"msid":118230184,"title":"GE HealthCare forecasts upbeat 2025 profit on steady medical device demand","entity_type":"ARTICLE","link":"/news/medical-devices/ge-healthcare-forecasts-upbeat-2025-profit-on-steady-medical-device-demand/118230184","link_next_mobile":"/news/medical-devices/ge-healthcare-forecasts-upbeat-2025-profit-on-steady-medical-device-demand/118230184?next=1","category_name":null,"category_name_seo":"medical-devices"}],"related_content":[],"seoschemas":false,"social_share":{"fb":"/information/medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast/118243419?utm_source=fb&utm_medium={{DEVICE_TYPE}}","x":"/information/medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast/118243419?utm_source=twitter&utm_medium={{DEVICE_TYPE}}","whatsapp":"/information/medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast/118243419?utm_source=wapp&utm_medium={{DEVICE_TYPE}}","linkdin":"/information/medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast/118243419?utm_source=linkedin&utm_medium={{DEVICE_TYPE}}","telegram":"/information/medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast/118243419?utm_source=telegram&utm_medium={{DEVICE_TYPE}}","copy":"/information/medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast/118243419?utm_source=copy&utm_medium={{DEVICE_TYPE}}"},"cat_msid":44909127,"cat_sub_msid":false,"msid":118243419,"entity_type":"ARTICLE","title":"Dexcom beats fourth-quarter gross sales, reiterates 2025 income forecast","synopsis":"The California-based system maker is pinning its hopes on Stelo, its lately launched system for adults aged 18 and older who don’t use insulin, making it the primary CGM obtainable for over-the-counter gross sales.","titleseo":"medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast","standing":"ACTIVE","authors":[],"analytics":{"feedback":0,"views":128,"shares":0,"engagementtimems":487000},"Alttitle":{"minfo":""},"next_promo_stories":[{"id":"117674599","type":"next_article"}],"artag":"Reuters","artdate":"2025-02-14 14:59:27","lastupd":"2025-02-14 15:01:39","breadcrumbTags":["Dexcom fourth-quarter sales","Dexcom revenue forecast","Stelo device","diabetes care","insulin-free CGM","Abbott Lingo","international expansion of Dexcom","CGM sales growth"],"secinfo":{"seolocation":"medical-devices/dexcom-beats-fourth-quarter-sales-reiterates-2025-revenue-forecast"}}” data-type=”information” id=”news_dtl_118243419″ page-title=”Dexcom beats fourth-quarter gross sales, reiterates 2025 income forecast”>

The California-based system maker is pinning its hopes on Stelo, its lately launched system for adults aged 18 and older who don’t use insulin, making it the primary CGM obtainable for over-the-counter gross sales.

Reuters

Up to date On Feb 14, 2025 at 03:01 PM IST

Learn by: 100 Business Professionals

Learn by 100 Business Professionals

Bengaluru: Medical system maker Dexcom beat fourth-quarter gross sales estimates helped by resilient demand for its steady glucose screens (CGMs) utilized by sufferers with diabetes.

Dexcom’s shares fell practically 37per cent final 12 months, largely attributable to a stoop in July after the corporate slashed its annual income forecast, blaming a restructuring of its gross sales crew, fewer clients and decrease income.

In July, the corporate stated that based mostly on the compounding impact of decrease second-quarter new buyer begins, it expects the expansion fee within the again half of the 12 months to be impacted.

It reiterated its earlier 2025 income estimate of $4.60 billion. Analysts on common had been anticipating income of $4.61 billion, as per information compiled by LSEG.

The corporate reported fourth-quarter income of $1.11 billion barely above the analysts’ consensus estimate of $1.10 billion.

Growing diabetes care consciousness, wider insurance coverage protection, and choice for units that don’t want finger pricks have benefited CGMs corresponding to Dexcom’s Stelo and G7. Rival Abbott launched its personal OTC CGM, Lingo, weeks after Dexcom’s Stelo debut.

The corporate is relying on additional worldwide enlargement to drive progress after it stated it had improved entry to its units in markets corresponding to Japan and France final quarter.

On an adjusted foundation, the corporate earned a revenue of 45 cents per share, in comparison with estimates of fifty cents per share.

(Reporting by Christy Santhosh in Bengaluru; Enhancing by Alan Barona)